Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

This treatment has been approved for sale to the public.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00377065
First received: September 14, 2006
Last updated: April 21, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This treatment has been approved for sale to the public.
  Study Completion Date: No date given
  Primary Completion Date: No date given